Rextone Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 30-12-2024
- Paid Up Capital ₹ 10.00 K
as on 30-12-2024
- Company Age 3 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 1267.97%
(FY 2023)
- Profit -234.51%
(FY 2023)
- Ebitda -224.54%
(FY 2023)
- Net Worth -386.47%
(FY 2023)
- Total Assets 67.34%
(FY 2023)
About Rextone Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 10.00 K , as per Ministry of Corporate Affairs (MCA) records.
Jay Hirpara, Hareshbhai Gondaliya, and Vishalkumar Hirpara serve as directors at the Company.
- CIN/LLPIN
U74999GJ2021PTC125744
- Company No.
125744
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Sep 2021
- Date of AGM
26 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Rextone Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jay Hirpara  | Director | 21-Sep-2021 | Current |
| Hareshbhai Gondaliya | Director | 21-Sep-2021 | Current |
| Vishalkumar Hirpara | Director | 21-Sep-2021 | Current |
Financial Performance of Rextone Pharmaceuticals.
Rextone Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1267.97% increase. The company also saw a substantial fall in profitability, with a 234.51% decrease in profit. The company's net worth observed a substantial decline by a decrease of 386.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rextone Pharmaceuticals?
In 2023, Rextone Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rextone Pharmaceuticals?
Rextone Pharmaceuticals has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rextone Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rextone Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
